Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
IN Control education series
Live webinar - Conducting a review of T2D patients in primary practice: A whole-of-practice approach
Thursday 23 June 2022, 7:00pm - 8:30pm AEST
In this webinar, A/Prof Ralph Audehm and another HCP colleague will take you through how their GP practices conduct a best-practice recall and review of their patients with T2D, using a whole-of-practice approach.
IN Control advanced course: INs and outs of INsulin INitiation and INtensification
This GP-led, on-demand advanced course, supported by diabetes specialists, will provide practical guidance on the role and implementation of insulin in the contemporary management of diabetes in the primary care space.
IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia
Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
Guide: Use of IDegAsp in T2D
Review practical recommendations from Australian diabetes experts on when and how to use IDegAsp (insulin degludec/insulin aspart) in real-world practice.
